GlassScriptPhysician profile
James Stathakios
NPI 1053351247
$3,409.73
in general payments reported to CMS, 2019-2025
42 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $147 · 2021: $317 · 2022: $701 · 2023: $536 · 2024: $446 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.74 | 2021-2025 | Botox, Ubrelvy |
| Collegium Pharmaceutical, INC. | $284.68 | 2019-2025 | Belbuca, Xtampza |
| Merz Pharmaceuticals, LLC | $263.37 | 2021-2024 | Xeomin |
| Scilex Pharmaceuticals INC. | $190.55 | 2019-2023 | Ztlido |
| Ipsen Biopharmaceuticals, INC | $178.06 | 2022-2025 | Dysport |
| Integra Lifesciences Corporation | $164.01 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Allergan, INC. | $158.87 | 2019-2022 | |
| Nevro Corp. | $113.86 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $98.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.92 | 2019-2022 | |
| Bioventus LLC | $95.96 | 2019-2025 | Durolane, Supartz Fx Sodium Hyaluronate, Xcell |
| Fidia Pharma USA INC. | $92.85 | 2022-2024 | Hymovis, Triluron |
| Averitas Pharma INC. | $86.06 | 2023-2025 | Qutenza |
| Pacira Therapeutics, INC. | $77.60 | 2019 | |
| Spr Therapeutics, INC | $74.29 | 2024-2025 | Sprint Pns System |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stathakios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.